Changes within microbial communities in arid topsoils in the western region of the United States can be correlated for the fırst time with global warming trends, according to microbiologist Ferran Garcia-Pichel of Arizona State University in Tempe and his collaborators there and at the Universidad Autónoma de Madrid in Madrid, Spain. Topsoil layers, which are rich in microbial content and activities, not only are crucial for controlling soil erosion but may also serve as indicators of climate change. Details appear in the June 28, 2013 Science (340: 1574 -1577 .
"The fındings . . . were not the result of a targeted effort to understand global warming effects on microbial distributions," says Garcia-Pichel. "Rather, it was an effort to see if biogeographic patterns of distribution were present in soil crust organisms." Based on DNA sequencing, two key topsoil cyanobacteria, Microcoleus vaginatus, which is psychrotolerant, and M. steenstrupii, which is thermotolerant, are critical for maintaining the health of thousands of other microbes that occupy topsoil. However, the recent data suggest that M. steenstrupii is outcompeting and might replace M. vaginatus as global temperatures continue to rise. Although the focus of the study was on microbial communities from Arizona, Oregon, New Mexico, Utah, and California, the fındings could apply to similar communities in other arid environments.
This replacement of cyanobacterial species is serious and constitutes a revealing example of how rising temperatures are affecting microbial distributions, according to Garcia-Pichel. "We can no longer neglect microbes and their distributions in impact evaluations of global climate change," he says. "One might now have to contend with effects that are not based simply on thermodynamics of metabolism, but much more on stochastic linkages between function and presence/absence of particular microbes. We would also like to explore the competition between these two microbial crust pioneers through time to see if there is a seasonal separation of growth periods." "I agree with the authors that higher temperatures may result in a shift of the microbial community structure, and that this phenomenon may cause the replacement of M. vaginatus by M. steenstrupii," says soil microbiologist Thomas Fischer from the Brandenburg University of Technology in Cottbus, Germany. "Temperature is the driving climatic factor for this possible replacement process in arid environments."
"This is a signifıcant study because it is the fırst I know which shows that microbial distributions may be affected by global climate change," says soil microbiologist Jeffrey Johansen at the John Carroll University in University Heights, Ohio. "We have really not begun to think much of what the impact might be on microbial communities. This article is also interesting because it shows how a cyanobacterium that was thought to be almost universally distributed in desert soils is actually restricted by temperature." Several new antimicrobial candidate drugs that share enzyme targets with fluoroquinolones but act through distinct binding sites dominated the poster summary session "Early New Antimicrobial Agents" at the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colo., last September. Other hopefuls include a narrow-spectrum DNA synthesis inhibitor that is active against Clostridium diffıcile, improved drug candidates that target the type III secretion apparatus of gram-negative bacterial pathogens, and a series of broad-spectrum ␤-lactamase inhibitors that help overcome resistance in pathogens to ␤-lactam antibiotics.
GSK2140944 (GSK944) is a novel bacterial topoisomerase inhibitor that differs from fluoroquinolones (FQ) in how it inhibits the same target enzymes, according to John Payne of GlaxoSmithKline (GSK) in Collegeville, Pa. Indeed, GSK944, which binds uncleaved DNA, is active against many bacterial pathogens that are resistant to FQ antibiotics, which bind instead to cleaved DNA, he says. X-ray crystallographic analysis confırms that the binding site of GSK944 on DNA gyrase differs from that of FQ antibiotics.
GSK944 is active against a range of conventional gram-positive bacterial pathogens as well as several biothreat pathogens, including Yersinia pestis and Bacillus anthracis. One pathogen against which it is not active is Chlamydia pneumoniae-"one of the surprises you get when working with a novel class," he says.
The benzisoxazoles are another group of antibacterial compounds that target DNA gyrase and topoisomerase, but with a mechanism that is distinct from FQ antibiotics (and presumably from GSK944, too), according to John Mueller of AstraZeneca in Waltham, Mass. These agents appear to have a dual target, at least when evaluated for activity against Staphylococcus aureus in vitro, he says. Among the benzisoxazoles, AZD0914 is "highly active" against clinical isolates of Neisseria gonorrheae, including those that are resistant to ciprofloxacin, he says. Whether it or other gyrase inhibitors in this class are similarly active against C. trachomatis, another sexually transmitted bacterial pathogen, remains to be tested.
Like FQ antibiotics, fused 2-pyridone compounds belonging to a newly disclosed PTC series are dual inhibitors of DNA gyrase and topoisomerase bacterial enzymes, according to Gary Karp of PTC Therapeutics in South Plainfıeld, N.J. Some compounds in this series show potent activity against a broad array of drug-resistant-including to fluoroquinolones-gram-negative and gram-positive bacterial pathogens, he says. Structural adjustments lead to some compounds within this series with "quite good activity against N. gonorrhea," including multipledrug-resistant isolates of this pathogen.
Although the structurally unrelated compound SMT19969 also inhibits DNA synthesis, its precise molecular target is not known but under study, according to Richard Vickers of Summit PLC in Abingdon, United Kingdom. This novel antimicrobial agent is "highly active and bactericidal" against C. diffıcile, he says. In part because of its narrow activity and apparent superiority to vancomycin, SMT19969 is already entered into clinical trials. It has another advantage in having little activity against other bacterial species of the gastrointestinal tract, including other clostridial species, based in part on analysis of fecal samples from the phase 1 clinical trial, he adds. A phase 2 clinical trial is planned for 2014.
MINITOPIC

GAO Report, Rep. DeLauro Raise Meat Safety Concerns
Officials of the US Department of Agriculture (USDA) need better information on a pilot project involving facilities for hogs and, separately, to bolster a proposed rule that affects inspections of poultry slaughter facilities, according to a report, "More Disclosure and Data Needed to Clarify Impact of Changes to Poultry and Hog Inspections," issued by the Government Accountability Office (GAO) last August. The GAO report criticizes the USDA Food Safety and Inspection Service (FSIS) for not thoroughly evaluating projects that are part of a broader effort to modernize food safety inspection procedures. In a related development, Representative Rosa DeLauro (D-CT) raised concerns with FSIS officials over "ongoing problems" with its Public Health Information System, saying that it continues to be "riddled with problems since its rollout over 2 years ago." Separately, Rep. DeLauro is objecting to USDA over its plans to grant "China's poultry processing plants standards of food safety equivalency to those in the United States." China's "food safety record should be deeply worrisome to American consumers," she says.
